Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–276.

Google Scholar 

Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727–38.

PubMed  PubMed Central  Google Scholar 

Willcocks L. ALIGNing the treatment of IgA nephropathy: reducing proteinuria with endothelin A receptor inhibition. Med. 2025. https://doi.org/10.1016/j.medj.2024.11.017.

Article  PubMed  Google Scholar 

Novartis. Atrasentan: US prescribing information. 2025. https://www.vanrafia-hcp.com/. Accessed 19 May 2025.

Heerspink HJL, Jardine M, Kohan DE, et al. Study design and baseline characteristics of ALIGN, a randomized controlled study of atrasentan in patients with IgA nephropathy. Kidney Int Rep. 2025;10(1):217–26.

PubMed  Google Scholar 

Novartis. Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) [media release]. 2 Apr 2025. https://www.novartis.com/.

Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10184):1937–47.

CAS  PubMed  Google Scholar 

de Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014;25(5):1083–93.

PubMed  PubMed Central  Google Scholar 

Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011;22(4):763–72.

CAS  PubMed  PubMed Central  Google Scholar 

Zonnenberg BA, Groenewegen G, Janus TJ, et al. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res. 2003;9(8):2965–72.

CAS  PubMed  Google Scholar 

Abbott Laboratories. FDA advisory committee does not recommend approval of XinlayTM (atrasentan) [media release]. 13 Sep 2005. https://www.abbott.com/.

AbbVie. Form 10-K 2017. 2018. https://investors.abbvie.com/. Accessed 14 May 2025.

Novartis. Novartis completes acquisition of Chinook Therapeutics [media release]. 11 Aug 2023. https://www.novartis.com/.

Chinook Therapeutics Inc. Chinook Therapeutics obtains worldwide rights from AbbVie to atrasentan with plans to develop for the treatment of kidney diseases [media release]. 10 Jan 2020. https://www.businesswire.com/.

Chinook Therapeutics Inc. Chinook Therapeutics announces formation of SanReno Therapeutics, a joint venture to develop kidney disease therapies in China [media release]. 30 Nov 2021. https://www.biospace.com/.

SanReno Therapeutics. SanReno Therapeutics announces acquisition by Novartis in pivotal transaction to bring forward transformative therapeutics in kidney disease [media release]. 5 Jan 2024. https://www.prnewswire.com/.

Cox J, Wu J, Naidu N, et al. Human renal mesangial cell activation induced by endothelin-1 or IgA nephropathy patient-derived immune complexes is blocked by selective ETa antagonist atrasentan [abstract no. POS-370]. Kidney Int Rep. 2021;6(4 Suppl):S160–1.

King A, Oballa R, Gunawan M, et al. Selective ETa antagonist atrasentan, rapidly reduces albuminuria and downregulates intra-renal pro-inflammatory and pro-fibrotic transcriptional networks in the gddY mouse model of spontaneous IgA nephropathy [abstract no. POS-378]. Kidney Int Rep. 2021;6(4 Suppl):S164.

Olson E, McConnell M, Ragan S, et al. Selective endothelin A receptor antagonist atrasentan attenuates mesangial cell injury, proteinuria and intra-renal proliferative, inflammatory and fibrotic transcriptional networks in a rat model of mesangioproliferative glomerulonephritis [abstract no. MO264]. Nephrol Dial Transplant. 2022;37(Suppl 3):I187–8.

Google Scholar 

Boels MG, Avramut MC, Koudijs A, et al. Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy. Diabetes. 2016;65(8):2429–39.

CAS  PubMed  Google Scholar 

Hudkins KL, Wietecha TA, Steegh F, et al. Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy. Am J Physiol Renal Physiol. 2020;318(5):F1295–305.

CAS  PubMed  Google Scholar 

Samara E, Dutta S, Cao G, et al. Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. J Clin Pharmacol. 2001;41(4):397–403.

CAS  PubMed  Google Scholar 

Verhaar MC, Grahn AY, Van Weerdt AW, et al. Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans. Br J Clin Pharmacol. 2000;49(6):562–73.

CAS  PubMed  PubMed Central  Google Scholar 

Heerspink HJL, Jardine M, Kohan DE, et al. Atrasentan in patients with IgA nephropathy. N Engl J Med. 2025;392(6):544–54.

CAS  PubMed  Google Scholar 

Barratt J, Kim SG, Inker LA, et al. AFFINITY study: 1-year results of atrasentan in IgA nephropathy [abstract no. FR-PO855]. J Am Soc Nephrol. 2024;35(Suppl 2):718.

Google Scholar 

Kim SG, Inker LA, Packham DK, et al. Atrasentan for the treatment of IgA nephropathy: interim results of the AFFINITY study [abstract no. WCN23-1126]. Kidney Int Rep. 2023;8(9):1902.

Google Scholar 

Barratt J, Vo N, Lee S, et al. AFFINITY study: 1Y results of atrasentan in IgAN in patients with UPCR <1 and ≥1g/g [abstract no. G-447 plus poster]. Am J Kidney Dis. 2025;85(4 Suppl 1):S140–1.

Google Scholar 

Kim SG, Akinfolarin AA, Inker LA, et al. Atrasentan in patients with proteinuric glomerular diseases: the AFFINITY study [abstract no. WCN23-1117 plus poster]. Kidney Int Rep. 2023;8(9):1902.

Google Scholar 

Noronha IL, Barratt J, Gorriz JL, et al. ASSIST: a randomized, double-blind, placebo-controlled crossover trial of atrasentan in patients with IgA nephropathy (IgAN) on SGLT2i [abstract no. WCN24-1868]. Kidney Int Rep. 2024;9(4):S178.

Google Scholar